Loading
Life sciences · Journal article
Journal of Computational Biology · September 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Targeted drug therapies offer a promising approach for treating complex diseases, with combinational drug therapies often employed to enhance therapeutic efficacy. However, unintended drug-drug interactions may undermine treatment outcomes or cause adverse side effects. In this work, we propose a novel joint learning framework for the simultaneous prediction of effective drug combinations and drug-drug interactions, based on coupled tensor-tensor factorization. Specifically, we model drug combination therapies and DDI by representing drug-drug-disease associations and drug-drug interaction profiles as coupled three-way tensors. To address the challenges of data incompleteness and sparsity, the proposed model integrates auxiliary drug similarity information, such as chemical structure similarities, drug-specific side effects, drug target profiles, and drug inhibition data on cancer cell lines, within a multi-view learning frame-work. For optimization, we adopt a modified Alternating Direction Method of Multipliers (ADMM) algorithm that ensures convergence while enforcing non-negativity constraints. In addition to standard tensor completion tasks, we further evaluate the proposed method under a more realistic new-drug prediction setting, where all interactions involving a previously unseen drug are withheld. This scenario closely aligns with real-world applications, in which reliable predictions for emerging or under-studied compounds are essential. We evaluate the proposed method on a comprehensive dataset compiled from multiple sources, including DrugBank, CDCDB, SIDER, and PubChem. Our experiments show that SI-ADMM maintains robust performance and achieves the best results comparing to other tensor factorization approaches, with or without auxiliary information, particularly in the new-drug prediction setting. The implementation of our method is publicly available at: https://github.com/Xiaoge-Zhang/SI-ADMM.